[1] PANTONI L. Cerebral small vessel disease：from

pathogenesis and clinical characteristics to

therapeutic challenges[J]. Lancet Neurol，2010，9

（7）：689-701.

[2] GORELICK P B，SCUTERI A，BLACK S E，et al.

Vascular contributions to cognitive impairment and

dementia：a statement for healthcare professionals

from the American Heart Association/American

Stroke Association[J]. Stroke，2011，42（9）：2672-

2713.

[3] MUNOZ D G，HASTAK S M，HARPER B，et

al. Pathologic correlates of increased signals of the

centrum ovale on magnetic resonance imaging[J].

Arch Neurol，1993，50（5）：492-497.

[4] WARDLAW J M，SMITH E E，BIESSELS G J，et

al. Neuroimaging standards for research into small

vessel disease and its contribution to ageing and

neurodegeneration[J]. Lancet Neurol，2013，12（8）：

822-838.

[5] BAMFORD J，SANDERCOCK P，DENNIS M，et

al. Classification and natural history of clinically

identifiable subtypes of cerebral infarction[J]. Lancet，

1991，337（8756）：1521-1526.

[6] ADAMS H P Jr，BENDIXEN B H，KAPPELLE L

J，et al. Classification of subtype of acute ischemic

stroke. Definitions for use in a multicenter clinical

trial. TOAST. Trial of Org 10172 in Acute Stroke

Treatment[J]. Stroke，1993，24（1）：35-41.

[7] GAO S，WANG Y J，XU A D，et al. Chinese

ischemic stroke subclassification[J/OL]. Front Neurol，

2011，2：6. https：//doi.org/10.3389/fneur.2011.00006.

[8] AMARENCO P，BOGOUSSLAVSKY J，CAPLAN

L R，et al. New approach to stroke subtyping：the

A-S-C-O（phenotypic）classification of stroke[J].

Cerebrovasc Dis，2009，27（5）：502-508.

[9] POTTER G，DOUBAL F，JACKSON C，et al.

Associations of clinical stroke misclassification

（'clinical-imaging dissociation'）in acute ischemic

stroke[J]. Cerebrovasc Dis，2010，29（4）：395-402.

[10] CHARIDIMOU A，NICOLL J A，MCCARRON M

O. Thrombolysis-related intracerebral hemorrhage

and cerebral amyloid angiopathy：accumulating

evidence[J/OL]. Front Neurol，2015，6：99. https：//

doi.org/10.3389/fneur.2015.00099.

[11] POWERS W J，RABINSTEIN A A，ACKERSON

T，et al. 2018 Guidelines for the early management of

patients with acute ischemic stroke：a guideline for

healthcare professionals from the American Heart

Association/American Stroke Association[J/OL].

Stroke，2018，49：e46-e110. https：//doi.org/10.1161/

STR.0000000000000158.

[12] WANG Y J，WANG Y L，ZHAO X Q，et al.

Clopidogrel with aspirin in acute minor stroke or

transient ischemic attack[J]. N Engl J Med，2013，

369（1）：11-19.

[13] SPS3 Investigators，BENAVENTE O R，HART R

G，et al. Effects of clopidogrel added to aspirin in

patients with recent lacunar stroke[J]. N Engl J Med，

2012，367（9）：817-825.

[14] TAI S Y，CHIEN C Y，CHANG Y H，et al.

Cilostazol use is associated with reduced risk

of dementia：a nationwide cohort study[J].

Neurotherapeutics，2017，14（3）：784-791.

[15] BLAIR G W，APPLETON J P，FLAHERTY

K，et al. Tolerability，safety and intermediary

pharmacological effects of cilostazol and isosorbide

mononitrate，alone and combined，in patients with

lacunar ischaemic stroke：the LACunar Intervention-1

（LACI-1）trial，a randomised clinical trial[J/OL].

EClinicalMedicine，2019，11：34-43. https：//doi.

org/10.1016/j.eclinm.2019.04.001.

[16] FISHER C M. Lacunes：small，deep cerebral

infarcts[J/OL]. Neurology，1965，15：774-784.

https：//doi.org/10.1212/wnl.15.8.774.

[17] WANG Y，XU J，ZHAO X，et al. Association of

hypertension with stroke recurrence depends on

ischemic stroke subtype[J]. Stroke，2013，44（5）：

1232-1237.

[18] DUFOUIL C，CHALMERS J，COSKUN O，et

al. Effects of blood pressure lowering on cerebral

white matter hyperintensities in patients with stroke：

the PROGRESS（Perindopril Protection Against

Recurrent Stroke Study）Magnetic Resonance

Imaging Substudy[J]. Circulation，2005，112（11）：

1644-1650.

[19] WEBER R，WEIMAR C，BLATCHFORD

J，et al. Telmisartan on top of antihypertensive

treatment does not prevent progression of cerebral

white matter lesions in the prevention regimen for

effectively avoiding second strokes（PRoFESS）MRI

substudy[J]. Stroke，2012，43（9）：2336-2342.

[20] SPS3 Study Group，BENAVENTE O R，COFFEY

C S，et al. Blood-pressure targets in patients with

recent lacunar stroke：the SPS3 randomised trial[J].

Lancet，2013，382（9891）：507-515.

[21] CROALL I D，TOZER D J，MOYNIHAN B，et al.

Effect of standard vs intensive blood pressure control

on cerebral blood flow in small vessel disease：the

PRESERVE randomized clinical trial[J]. JAMA

Neurol，2018，75（6）：720-727.

[22] SPRINT MIND Investigators for the SPRINT

Research Group，NASRALLAH I M，PAJEWSKI

N M，et al. Association of intensive vs standard

blood pressure control with cerebral white matter

lesions[J]. JAMA，2019，322（6）：524-534.

[23] WHITE W B，MARFATIA R，SCHMIDT J，et al.

INtensive versus standard ambulatory blood pressure

lowering to prevent functional DeclINe in the ElderlY

（INFINITY）[J]. Am Heart J，2013，165（3）：258-

265，e1.

[24] Stroke Prevetion by Aggressive Reduction in

Cholestrol Levels（SPARCL）Investigators，

KARAM J G，LONEY-HUTCHINSON L，et al.

High-dose atorvastatin after stroke or transient

ischemic attack：the Stroke Prevention by Aggressive

Reduction in Cholesterol Levels（SPARCL）

Investigators[J]. J Cardiometab Syndr，2008，3（1）：

68-69.

[25] TEN DAM V H，VAN DEN HEUVEL D M，VAN

BUCHEM M A，et al. Effect of pravastatin on

cerebral infarcts and white matter lesions[J].

Neurology，2005，64（10）：1807-1809.

[26] KIM B J，LEE E J，KWON S U，et al. Prevention

of cardiovascular events in Asian patients with

ischaemic stroke at high risk of cerebral haemorrhage

（PICASSO）：a multicentre，randomised controlled

trial[J]. Lancet Neurol，2018，17（6）：509-518.

[27] CAVALIERI M，SCHMIDT R，CHEN C，et al. B

vitamins and magnetic resonance imaging-detected

ischemic brain lesions in patients with recent

transient ischemic attack or stroke：the VITAmins

TO Prevent Stroke（VITATOPS）MRI-substudy[J].

Stroke，2012，43（12）：3266-3270.

[28] SHI Y，WARDLAW J. Update on cerebral small

vessel disease：a dynamic whole-brain disease[J].

Stroke Vasc Neurol，2016，1（3）：83-92.

[29] WARDLAW J M，CHAPPELL F M，VALDÉS

HERNÁNDEZ M D C，et al. White matter

hyperintensity reduction and outcomes after minor

stroke[J]. Neurology，2017，89（10）：1003-1010.

[30] SHOAMANESH A，PREIS S R，BEISER A S，et

al. Inflammatory biomarkers，cerebral microbleeds，

and small vessel disease：Framingham Heart

Study[J]. Neurology，2015，84（8）：825-832.

[31] Han J H，Wong K S，Wang Y Y，et al. Plasma

level of sICAM-1 is associated with the extent of

white matter lesion among asymptomatic elderly

subjects[J]. Clin Neurol Neurosurg，2009，111（10）：

847-851.

[32] WARDLAW J M，SMITH C，DICHGANS M.

Small vessel disease：mechanisms and clinical

implications[J]. Lancet Neurol，2019，18（7）：684-

696.

[33] 倪俊，徐运. 脑小血管病转化医学研究中国专家共识

[J]. 中国卒中杂志，2018，13（8）：853-870.

[34] BATH P M，WARDLAW J M. Pharmacological

treatment and prevention of cerebral small vessel

disease: a review of potential interventions[J]. Int J

Stroke，2015，10（4）：469-478.